MHRA (UK)Original article
UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
RegulatoryGabapentin Relonchem 50mg/ml Oral SolutionNegative
AI Analysis
Summary
Relonchem Limited notified the MHRA of a Class 4 medicines defect for Gabapentin Relonchem 50mg/ml Oral Solution due to particles observed in some bottles, identified through a customer complaint.
Outcome Details
Class 4 Medicines Defect Notification issued for particle contamination in some bottles
Importance:4/10
Sentiment:
-0.80
product_defectquality_issueMHRAregulatory_notificationparticle_contaminationoral_solution
Read the original article
Published by MHRA (UK) on July 7, 2026 2:34 PM